Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)

Table 1 Baseline characteristics separately for patients in the infliximab and placebo arm

	Infliximab (n = 16)	Placebo (n = 7)	p
Male gender, n (%)	11 (68.8)	7 (100.0)	0.27
Age, years	38.6 (11.6)	44.9 (5.8)	0.19
Disease duration, years	8.3 (8.2)	11.5 (7.4)	0.37
HLA-B27 positive, n (%)	14 (87.5)	5 (71.4)	0.56
History of uveitis, n (%)	6 (37.5)	1 (14.3)	0.37
History of psoriasis, n (%)	0 (0.0)	0 (0.0)	–
History of IBD, n (%)	2 (12.5)	1 (14.3)	1.00
BASDAI score, 0–10	7.0 (1.3)	7.1 (0.7)	0.55
BASFI score, 0–10	6.3 (1.5)	7.2 (1.3)	0.21
Patient’s global assessment, 0–10 VAS	6.8 (1.4)	7.8 (1.2)	0.15
Mander enthesis index, 0–90	7.7 (8.6)	12.8 (14.6)	0.69
Swollen joint index, 0–44	2.9 (3.7)	3.0 (3.9)	0.86
Chest expansion, cm	2.0 (0.9)	2.5 (2.0)	0.87
Night pain, 0–10 VAS	6.4 (2.0)	7.4 (1.0)	0.11
CRP level, mg/L	26.0 (24.4)	15.4 (16.0)	0.22
Increased CRP, n (%)*	13 (81.3)	6 (85.7)	1.00
CES-D score, 0–60	15.5 (9.3)	17.3 (5.7)	0.66
Increased CES-D, n (%)^†	9 (56.3)	3 (42.9)	0.67

Values expressed as mean (SD), unless otherwise indicated
HLA-B27 human leucocyte antigen-B27, IBD inflammatory bowel disease, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, VAS visual analog scale, CRP C-reactive protein, CES-D Center for Epidemiologic Studies Depression Scale
*Defined as CRP > 5 mg/L
^†Defined as a score ≥ 16, indicating possible depression

ISSN: 1478-6362